# Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)

> **NCT01396057** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 244 (actual)

## Conditions studied

- Visual Impairment
- Macular Edema
- Branch Retinal Vein Occlusion

## Interventions

- **DRUG:** Ranibizumab
- **OTHER:** Dexamethasone Implant
- **OTHER:** Sham injection

## Key facts

- **NCT ID:** NCT01396057
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2014-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01396057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01396057, "Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01396057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*